skip to Main Content

Recommendations for Pancreatic Cancer Are Added to Guidelines for Genetic Testing in Patients With High Risk

Recommendations for Pancreatic Cancer Are Added to Guidelines for Genetic Testing in Patients With High Risk
The current national Comprehensive Cancer Network (NCCN) Guidelines for Genetic/Familial High-Risk Assessment, Version 1.2020, have been expanded to provide information about pancreatic cancer in addition to recommendations regarding genetic testing in patients with breast and ovarian cancer.

This update was necessary because of evidence suggesting that a sufficient number of patients with pancreatic cancer carry alterations in high-penetrance breast and ovarian cancer susceptibility genes that warrant testing, including BRCA1BRCA2CDH1PALB2PTEN, and TP53, among others.1 Identifying a mutation in 1 of these genes in a patient could have significant implications for clinical decision making. Read more . . . 


Back To Top